VivoSeq
Dermatology

Toxic Epidermal Necrolysis

9

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Toxic Epidermal Necrolysis is an early-stage landscape with 9 programs across 6 companies. The most active players are Pfizer, Prism Pharmaceuticals, Johnson & Johnson. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

29/100

Attrition Rate

56/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1P

Prism Pharmaceuticals

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Sanofi logo

Sanofi

2 programs

ApprovedN

Nihon Pharmaceutical Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

6 of 10 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody330%Protein / enzyme110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

9

clinical trials

Withdrawn4 · 44%
Completed2 · 22%
Recruiting1 · 11%
Terminated1 · 11%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Recruiting·—·Phase 1·NCT06119490·30 enrolled
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Not yet recruiting·HHospices Civils de Lyon·Phase 1/2·NCT07110662·9 enrolled
G-CSF in the Treatment of Toxic Epidermal Necrolysis
Completed·UUniversity of Liege·Phase 4·NCT02739295·10 enrolled
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Completed·NNihon Pharmaceutical Co., Ltd·Phase 3·NCT01696500·10 enrolled
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Terminated·—·Phase 1/2·NCT02037347·1 enrolled
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
Withdrawn·LLoyola University·Phase 2·NCT00372723
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
Withdrawn·MMassachusetts General Hospital·N/A·NCT03585946
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
Withdrawn·UUniversity of California, Davis·Phase 1/2·NCT02319616
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Withdrawn·MMassachusetts Eye and Ear Infirmary·Phase 1/2·NCT01256489

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)